✦ LIBER ✦

123 Discussion of toxicity and biomarkers in a phase i trial of gefitinib (IRESSATM) in combination with radiation or chemo-radiation for patients with locally advanced head and neck cancer (LAHNC)

✍ Scribed by D. Raben; C. Chen; M. Kane; J. Song; G. Eckhardt; A. Meyers; K. McCoy; A. Raben; H. Quon; K. Hu; J. Dancey

Book ID: 119517653
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 139 KB
Volume: 78
Category: Article
ISSN: 0167-8140
DOI: 10.1016/s0167-8140(06)80602-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

649 Update on the toxicity and response

649 Update on the toxicity and response of a phase I trial of concurrent, daily gefitinib and radiation or chemo-radiation for patients with locally advanced squamous cell cancer of the head and neck (LASCCHN)

✍ D. Raben; M. Kane; C. Chen; J. Song; L. Brualdi; A. Raben; K. Hu; S. Gollamudi; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 146 KB

Chemotherapy Dose Escalation Might Not I

Chemotherapy Dose Escalation Might Not Improve The Outcome Of Concurrent Chemo-radiation Treatment In Patients With Locally Advanced Head and Neck Cancer (LAHNC) Patients

✍ Skladowski, K.A.; Wygoda, A.; Cedrych, I.; Rutkowski, T.; Hutnik, M.; Pilecki, B 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 37 KB

A Phase I Study of Cetuximab in Combinat

A Phase I Study of Cetuximab in Combination with Gemcitabine and Radiation for Locally Advanced Pancreatic Cancer

✍ A.B. Chakravarthy; J.D. Berlin; A.C. Lockhart; E. Chan; A. Parikh; V. Kordowski; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Evaluation of prognostic factors and two

Evaluation of prognostic factors and two radiation techniques in patients treated with surgery followed by radio(chemo)therapy or definitive radio(chemo)therapy for locally advanced head-and-neck cancer

✍ Dirk Rades; Monika Stoehr; Thekla Meyners; Guenther Bohlen; Roger Nadrowitz; Jue 📂 Article 📅 2008 🏛 Springer 🌐 German ⚖ 530 KB

A phase I clinical trial of prolonged in

A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck

✍ Jonathan J. Beitler; Richard V. Smith; Hilda Haynes; Carl E. Silver; Astrid Quis 📂 Article 📅 1998 🏛 Springer US 🌐 English ⚖ 67 KB

Neurotoxicity in a phase I trial of cont

Neurotoxicity in a phase I trial of continuous-infusion cisplatin with hyperfractionated radiotherapy for locally advanced head and neck cancer

✍ Gerald H. Clamon; Lynn Baatz; Henry T. Hoffman; David H. Hussey; Matthew Glascoc 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 569 KB

## Background: Both twice daily fractionated radiotherapy and concurrent cisplatin with once-daily radiotherapy have been shown to improve local disease control in patients with head and neck cancer. the objective of this phase i trial was to determine the maximum tolerated dose of cisplatin which